Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - phenylbutazone - oral paste - phenylbutazone analgesic active 200.0 mg/ml - musculoskeletal system - horse | pony | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pace - analgesic | anti-inflammatory agent | musculoskeletal conditions | soft tissue injury | antipyretic | arthritis | arthrosis | bone soreness | bruising | bursitis | colic | external myopathy | inflamation of soft tissues an | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle relaxant | muscle soreness | osteitis | osteoarthritis | platelet activity | rheumatism | sedative | spasmolytic | sprains | strains | tendon and ligament sprains | tendon sprains | tendonitis | tenosynovitis | traumatic joint and connective | traumatic swelling

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - econazole nitrate - topical cream, ointment, paste, gel, lotion - econazole nitrate imidazole active 10.0 mg/g - dermatological preps. - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - dermatophyte infection (ringworm) | mycotic dermatitis | pathogenic mould | pathogenic yeast | ringworm | trichophyton mentagrophytes

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - sodium chloride; sodium citrate - parenteral liquid/solution/suspension - sodium chloride mineral-sodium-salt active 38.0 g/l; sodium citrate mineral-sodium-salt active 38.0 g/l - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - dehydration | electrolyte replacement

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - di-isopropylamine dichloroacetate; sodium gluconate - parenteral liquid/solution/suspension - di-isopropylamine dichloroacetate ungrouped active 20.0 mg/ml; sodium gluconate mineral-sodium-salt active 19.0 mg/ml - cardiovascular system - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - vascular system reactant | cardiac stimulant | coronary vasodilator | navicular disease | reactants on vascular system | respiratory stimulant | tick paralysis | vascular system | vasodilation

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - ranitidine hydrochloride - oral paste - ranitidine hydrochloride furan active 220.0 mg/ml - miscellaneous veterinary - horse | horse foal | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare - gastric ulcers | heal/reduce gastric ulceration

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - hydroxyprogesterone caproate - parenteral liquid/solution/suspension - hydroxyprogesterone caproate steroid-progestin active 100.0 mg/ml - endocrine system - horse mare (female) | female horse - anabolic steroid | abortion threat | androgenic properties | bone repair | catabolic complications | convalescence | erythropoietic activity | geriatric therapy | improve appetite | male sexual characterisitics | muscle development | non-virilising anabolic | pathophysiological process | protein and mineral anabolic | skeletal conditions | tissue breakdown | tissue repair | virilising anabolic

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - nicotinic acid; choline chloride; pantothenol-d = panthenol-d; vitamin b2 phosphate sodium = riboflavin phosphate sodiu; vitamin b1 hydrochloride = thiamine hydrochloride; vitamin b6 hydrochloride = pyridoxine hydrochloride - parenteral liquid/solution/suspension - nicotinic acid alkaloid active 50.0 mg/ml; choline chloride vitamin-b complex active 5.0 mg/ml; pantothenol-d = panthenol-d vitamin-b5 active 20.0 mg/ml; vitamin b2 phosphate sodium = riboflavin phosphate sodiu vitamin-b2 active 2.0 mg/ml; vitamin b1 hydrochloride = thiamine hydrochloride vitamin-b1 active 50.0 mg/ml; vitamin b6 hydrochloride = pyridoxine hydrochloride vitamin-b6 active 10.0 mg/ml - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - choline deficiency | vitamin b deficiency

Singapore - engleză - HSA (Health Sciences Authority)

emergo singapore consulting private limited - general hospital - the provizio sem scanners are intended as an adjunct to current standard of care for the detection of deep and early-stage pressure-induced injuries/ulcers by health care professionals.

Singapore - engleză - HSA (Health Sciences Authority)

ids medical systems (singapore) pte ltd - dental - the dental ct scanner axr is designed to obtain radiological images of the oral anatomy, including teeth, maxillofacial areas, oral structures, carpal images and head-neck bone regions, and the same system, use should be handled by health professionals with qualification and duly qualified.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - gadoxetate disodium (unii: hoy74vze0m) (gadolinium cation (3+) - unii:azv954tz9n) - gadoxetate disodium 181.43 mg in 1 ml - eovist is indicated for intravenous use in magnetic resonance imaging (mri) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease. eovist is contraindicated in patients with history of severe hypersensitivity reactions to eovist [see warnings and precautions ( 5.3 )] . gbcas have been shown to cross the human placenta and result in fetal exposure and gadolinium retention. the human data on the association between gbcas and adverse fetal outcomes are limited and inconclusive (see data). in animal reproduction studies, no teratogenicity was observed with repeated daily intravenous administration of gadoxetate disodium to rats during organogenesis at doses up to 32 times the recommended single human dose; however, an increase in preimplantation loss was noted at doses 3.2 times the single human dose. post implantation loss was observed with repeated daily intravenous administration of gadoxetate disodium to rabbits on gestation days 6 through 18 at doses 26 times the recommended single human dose (see data) . because of the potential risks of gadolinium to the fetus, use eovist only if imaging is essential during pregnancy and cannot be delayed. the background risk in the u.s. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. contrast enhancement is visualized in the placenta and fetal tissues after maternal gbca administration. cohort studies and case reports on exposure to gbcas during pregnancy have not reported a clear association between gbcas and adverse effects in the exposed neonates. however, a retrospective cohort study, comparing pregnant women who had a gbca mri to pregnant women who did not have an mri, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving gbca mri. limitations of this study include a lack of comparison with non-contrast mri and lack of information about the maternal indication for mri. overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of gbcas in pregnancy. animal data gbcas administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, kidney, and spleen for at least 7 months. gbcas administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one month postnatal age. animal reproductive and developmental toxicity studies were done in rats and rabbits. gadoxetate disodium was not teratogenic when given intravenously during organogenesis to pregnant rats at doses up to 32 times the recommended single human dose (mmol/m2 basis). however, an increase in preimplantation loss was noted at 3.2 times the human dose (mmol/m2 basis). compared to untreated controls, rates of postimplantation loss and absorption increased and litter size decreased when pregnant rabbits received gadoxetate disodium at doses 26 times the recommended human single dose (mmol/m2 basis). this occurred without evidence of maternal toxicity. because pregnant animals received repeated daily doses of gadoxetate disodium, their overall exposure was significantly higher than that achieved with the standard single dose administered to humans. risk summary there is no information regarding the presence of gadoxetate disodium in human milk, the effects of the drug in a breastfed infant, or the effects of the drug on milk production. however, published lactation data on other gbcas report that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk and there is limited gbca gastrointestinal absorption in the breastfed infant. in rat lactation studies with [153 gd] gadoxetate disodium, less than 0.5% of the total administered radioactivity was transferred to the nursing pup. clinical considerations a lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for up to 10 hours after eovist administration in order to minimize exposure to a breastfed infant. data animal data in lactating rats given 0.1 mmol/kg [153 gd] gadoxetate disodium, less than 0.5% of the total administered radioactivity was transferred to the neonates via maternal milk, mostly within 2 hours. adequate and well-controlled studies of eovist in pediatric patients have not been conducted. an observational study with eovist was performed in 52 patients (aged > 2 months and < 18 years) referred for evaluation of suspected or known focal liver lesions. eovist improved border delineation and increased contrast of the primary lesion in the majority of patients when compared to non-contrast images. no safety issues were identified. no dose adjustment according to age is necessary in pediatric patients. the safety and effectiveness of eovist have not been established in premature infants. nsf risk no case of nsf associated with eovist or any other gbca has been identified in pediatric patients ages 6 years and younger. juvenile animal data single and repeat-dose toxicity studies in neonatal and juvenile rats did not reveal findings suggestive of a specific risk for use in pediatric patients including term neonates and infants. in clinical studies of eovist, 674 (34%) patients were 65 years of age and over, while 20 (1%) were 80 years of age and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, use of eovist in an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. in a clinical pharmacology study, slight to moderate differences in pharmacokinetic parameters of gadoxetate disodium (increased auc and terminal half-life, decreased total clearance) were found in a group of geriatric volunteers in comparison to non-geriatric volunteers. no clinically relevant differences in liver contrast enhancement were found. in a clinical pharmacology study in a group of patients with moderate renal impairment, a moderate increase in auc and terminal half-life was observed in comparison to healthy volunteers with normal renal function. hepatic contrast did not differ among the groups. end-stage renal failure may impair eovist imaging performance [see warnings and precautions (5.6)]. in a study of patients with end-stage renal failure, the terminal half-life was prolonged about 12-fold and the auc was increased about 6-fold. hepatic contrast was markedly reduced in these patients, which was attributed to significantly elevated serum ferritin levels [see warnings and precautions ( 5.2 )] . approximately 30% of the injected dose was removed by dialysis in a single 3-hour dialysis session, which started one hour after an eovist dose. eovist was almost completely eliminated via dialysis and biliary excretion within the observation period of 6 days, predominantly within the first 3 days. in a clinical pharmacology study in groups of patients with mild or moderate hepatic impairment, a slight to moderate increase in plasma auc, half-life and urinary excretion, as well as decrease in hepatobiliary excretion was observed in comparison to healthy subjects with normal liver function. hepatic contrast signal did not differ among the groups. severe hepatic impairment may impair eovist imaging performance [see warnings and precautions (5.6)] . in patients with severe hepatic impairment, especially in patients with abnormally high (> 3 mg/dl) serum bilirubin levels, the auc was increased up to 60% and the elimination half-life was increased up to 49%. the hepatobiliary excretion substantially decreased to about 5% of the administered dose and reduced hepatic contrast signal was observed. a dose adjustment is not necessary for patients with hepatic impairment. in clinical studies, 489 patients had a diagnosis of liver cirrhosis (child-pugh category a, n = 270; category b, n = 98; category c, n = 24; unknown category, n = 97). no difference in diagnostic performance and safety was observed among these patients.